Journal
CANCER
Volume 118, Issue 4, Pages 1130-1137Publisher
WILEY-BLACKWELL
DOI: 10.1002/cncr.26358
Keywords
adolescent; rhabdomyosarcoma; toxicity; chemotherapy; age; sex
Categories
Funding
- NCI NIH HHS [U10 CA98413-08, U10 CA072989-06, U10 CA024507-25, U10 CA072989-05, U10 CA98543-08, U10 CA098413-04, U10 CA072989-04, U10 CA024507-22, U10 CA072989-03, U10 CA072989, U10 CA024507-24, U10 CA098413, U10 CA024507, U10 CA098543, U10 CA24507, L40 CA103665, U10 CA024507-23, U10 CA098413-05, U10 CA024507-26] Funding Source: Medline
Ask authors/readers for more resources
BACKGROUND: Patients aged >10 years with rhabdomyosarcoma have an inferior outcome compared with patients ages 1 to 9 years, which may be explained by toxicities (adverse events [AEs]) that result in chemotherapy dose reductions. METHODS: AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded. The incidence of toxicities by age and treatment regimen was determined. The odds of developing AEs in a particular age group (ages 5-9 years, 10-14 years, and 15-20 years) were compared with the odds in the control group of patients ages 1 to 4 years. RESULTS: In total, 657 patients were eligible for analysis. The estimated 5-year event-free survival rates were 78%, 83%, 67%, and 58% for the groups ages 1 to 4 years, 5 to 9 years, 10 to 14 years, and 15 to 20 years, respectively. Patients ages 15 to 20 years experienced less neutropenia (odds ratio [OR], 0.43; P <.0001), thrombocytopenia (OR, 0.41; P <.0001), anemia (OR, 0.34; P <.0001), and infection (OR, 0.41; P <.0001) compared with younger patients, although they received similar amounts of chemotherapy. In contrast, peripheral nervous system toxicity was higher in adolescents aged > 10 years (OR, 4.18; P <.0001). Females experienced more neutropenia (OR, 1.28; P.05) and thrombocytopenia (OR, 1.26; P.06) compared with males. CONCLUSIONS: Adolescents who received treatment for rhabdomyosarcoma experienced significantly less hematologic toxicity and more peripheral nervous system toxicity compared with younger children despite receiving similar amounts of chemotherapy. Although outcomes were inferior in adolescents, it was unclear whether the differences in toxicity observed in the current study had an impact on outcome. The authors concluded that future studies examining the age-related and sex-related differences in pharmacokinetics of chemotherapy are necessary. Cancer 2012; 118: 1130-7. VC 2011 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available